US FDA delays decision on HIV prevention pill
(Reuters) - U.S. regulators have delayed until mid-September a decision on whether to approve Gilead Sciences' HIV pill Truvada for preventing the infection, citing the need to review the company's risk mitigation plan, Gilead said on Friday.
Shares of the company closed up 1.3 percent at $49.64 on Nasdaq.
An advisory panel to the Food and Drug Administration last month recommended that the agency approve Truvada as a treatment for preventing HIV infection among people at risk for contracting AIDS, including homosexual and bisexual men.
Opponents of the move have argued that the drug has shown to be only partially effective in preventing transmission of the virus and protection is dependent on taking a pill every day -- a regimen which healthy people may not remember to adhere to.
During the advisory panel last month, members expressed concern about prospective FDA guidelines that call for education and training for prescribing physicians but avoid basic restrictions on the availability of the treatment.
Some said drug recipients should be required to undergo regular HIV screening to prevent them from becoming HIV positive while taking the treatment and unknowingly passing drug-resistant HIV strains to their sexual partners.
Studies showed Truvada to be more than 90 percent effective at preventing HIV infection among test subjects who took the drug as prescribed, but only 44 percent effective among test populations that included intermittent use.
"Our earlier survey of high-volume HIV specialists indicated that difficulties related to cost, resistance, and compliance will make broad uptake of Truvada PrEP challenging, which in totality suggests limited commercial impact in the prevention setting," UBS analyst Matthew Roden said in a research note.
The term "PrEp" is shorthand for pre-exposure prophylaxis.
The AIDS Healthcare Foundation estimated the cost for someone to use Truvada for preventing transmission of HIV at $14,000 a year.
Truvada combines Gilead's HIV drugs Emtriva, also known as emtricitabine, with Viread, or tenofovir. It already has FDA approval to treat people infected with the human immunodeficiency virus that causes AIDS.
Nearly 1.2 million Americans are infected with HIV.
The new deadline for a decision from the FDA is Sept. 14. If approved, Truvada would be the first drug for use as a preventive treatment for HIV in the United States.
Sign Up for Free Newsletters
Ask Your Doctor the RIGHT Questions!
the most from your doctor visit.
Emailed right to you!
The Ask Your Doctor email series
may contain sponsored content.
18+, US residents only please.
Get the MOST from QualityHealth
- Top Searches
- 1. Arthritis Management: Nature Heals
- 2. 5 Digestive To-Dos
- 3. Men: Should You Shave It or Leave It?
- 4. Today's Top Fitness Trends
- 5. Sugar and Osteoarthritis : The Link
- 6. Can't Afford Your Hospital Bills?
- 7. Stay Energized All Day Long
- 8. Phobias: Who Has Them and Why?
- 9. What If Your EpiPen Fails?
- 10. 5 Costly Medical Billing Mistakes
- 1. Ice Falls Can Cause Serious Injuries
- 2. Can Inactivity Act Like a Disease?
- 3. Kale Snack Recipe for Diabetics
- 4. How Running Affects Arthritis
- 5. Sugar and Your Immunity System
- 6. Do Weight Loss Supplements Work?
- 7. 5 Super Foods for Spring
- 8. The Hazards of Reusable Bags
- 9. How to Avoid Ingrown Hairs
- 10. Health Tip: Constantly Change Shoes
- 1. 4 Common Treatments for Epilepsy
- 2. What Does a Urogynecologist Do?
- 3. GERD Without Heartburn? It's Possible
- 4. Graston Technique: Can It Work on You?
- 5. Music Therapy Can Help Autism
- 6. 8 Ways to Fight MS-Related Fatigue
- 7. Can You Still Bleed After Menopause?
- 8. Be Your Own Health Care Advocate
- 9. Why Is Syphillis on the Rise?
- 10. Ideal Weight vs. Happy Weight
The material on the QualityHealth Web site is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a physician or other qualified health provider. See additional information.